home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

448.80 -3.33 (-0.74%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

69 70 Next >

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗

November 05, 2024

Via Benzinga

Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday? ↗

November 05, 2024

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes for the 47th president.

Via Benzinga

5 Top Stocks to Buy in November ↗

November 05, 2024

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.

Via The Motley Fool

Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts ↗

November 05, 2024

Via Benzinga

Looking Into Vertex Pharmaceuticals's Recent Short Interest ↗

October 21, 2024

Via Benzinga

Market Whales and Their Recent Bets on VRTX Options ↗

October 18, 2024

Via Benzinga

My 2 Favorite Growth Stocks to Buy Hand Over Fist in November ↗

November 05, 2024

The sky's the limit for these stocks.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

VRTX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms ↗

November 04, 2024

Vertex Pharmaceuticals beat third-quarter expectations on Monday. The company also raised its sales outlook.

Via Investor's Business Daily

Vertex Reports Third Quarter 2024 Financial Results

November 04, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday? ↗

November 04, 2024

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday.

Via Benzinga

Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts? ↗

November 04, 2024

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend.

Via Benzinga

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers ↗

November 02, 2024

It won't be able to be profitable without hitting its targets for both of these figures.

Via The Motley Fool

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗

November 01, 2024

Amid the election, and a Fed rate vote, earnings season roars ahead.

Via Investor's Business Daily

Topics Economy Stocks

Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies' ↗

October 31, 2024

Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added.

Via Benzinga

Vertex to Participate in Upcoming November Investor Conferences

October 29, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years ↗

October 28, 2024

Via Benzinga

These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself? ↗

October 28, 2024

A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts.

Via Benzinga

Topics Government Stocks

12 High-Growth Stocks That Could Deliver Parabolic Returns ↗

October 28, 2024

These 12 innovative companies could deliver exponential returns over the next quarter century.

Via The Motley Fool

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

October 25, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Smartest Growth Stock to Buy With $500 Right Now ↗

October 25, 2024

This stock might not be available for under $500 for long.

Via The Motley Fool

Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits ↗

October 24, 2024

Its latest report of clinical data suggests it has a winner on its hands.

Via The Motley Fool

Why We Buy Stocks ↗

October 21, 2024

Is fear of missing out (FOMO) controlling your portfolio?

Via The Motley Fool

Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030 ↗

October 19, 2024

There's no need to change a winning formula.

Via The Motley Fool

Topics Stocks

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

October 18, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings) ↗

October 17, 2024

Via Benzinga

Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

October 16, 2024

Via Benzinga

Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever ↗

October 13, 2024

These profitable companies are facing long-term growth runways.

Via The Motley Fool

3 No-Brainer Growth Stocks to Buy in October ↗

October 13, 2024

These stocks look like slam-dunk picks for growth investors.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com